PV Bulletin
Health Canada

Health Canada reposts device recall forms and updates GVP GUI-0102

Health Canada lists FRM-0360A/FRM-0360B for device recall reporting and shows GUI-0102 GVP guidance issued/implemented May 22, 2026.

Primary source: Canada.ca (Health Canada) – Good pharmacovigilance practices guidelines (GUI-0102)

PV Impact Brief

Urgency: HighConfidence: medium

What changed

Health Canada lists FRM-0360A/FRM-0360B for device recall reporting and shows GUI-0102 GVP guidance issued/implemented May 22, 2026.

Why it matters

Potential impact spans Local Affiliate Compliance, Device Vigilance, Inspection Readiness, Regulatory Intelligence Monitoring, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Action needed

Health Canada update requires triage for Local Affiliate Compliance, Device Vigilance, Inspection Readiness; confirm local obligations and document follow-up actions.

Relevant for
Local Safety OfficerRegulatory Intelligence LeadMedical Device Vigilance LeadPV Quality LeadQPPV
Processes impacted
Local Affiliate ComplianceDevice VigilanceInspection ReadinessRegulatory Intelligence Monitoring
Owner

Local Safety Officer

Review cadence

Immediate triage (within 1 business day), then weekly review until closure.

Evidence and confidence

Confidence: mediumSource update date not verified — confirm on the regulator site before acting

Primary-source confirmation recommended before operational implementation.

Full briefing

Practical implication

Health Canada update requires triage for Local Affiliate Compliance, Device Vigilance, Inspection Readiness; confirm local obligations and document follow-up actions.

Health Canada has pointed industry to specific, named medical device recall reporting forms on its compliance/enforcement pages and has also posted updated metadata for its Good Pharmacovigilance Practices (GVP) guidance.

On Health Canada’s compliance and enforcement “What’s new” page, the regulator lists the “Medical device initial recall reporting form (FRM-0360A)” and the “Medical device final recall reporting form (FRM-0360B),” both dated 2025-05-08. Health Canada’s “Compliance and enforcement of medical devices - Forms, guidance, policies and laws” landing page also links FRM-0360A and FRM-0360B under “Recall reporting for medical devices.”

For pharmacovigilance and device vigilance teams, this creates an immediate document-control checkpoint. Any company conducting medical device recalls in Canada (including manufacturers, importers, and distributors that submit recall reports) should confirm that internal controlled templates, working instructions, and recall checklists reference the correct form IDs (FRM-0360A for initial reporting and FRM-0360B for final reporting) and align with the fields on the currently posted forms.

Separately, Health Canada’s “Good pharmacovigilance practices guidelines (GUI-0102)” page indicates the guidance was issued May 22, 2026 and implemented May 22, 2026. The page also states that this version replaces the prior GUI-0102 implemented August 11, 2013. While the fact pattern available here is limited to the issuance/implementation metadata and replacement statement, the change is relevant to drug manufacturers/market authorization holders subject to Health Canada GVP inspections.

In practical terms, PV Quality and inspection-readiness teams may want to treat the May 22, 2026 GUI-0102 as the current Health Canada GVP reference point and perform a targeted gap assessment versus existing Canada PV SOPs and inspection-readiness materials, especially where content is explicitly framed around regulator expectations.

Operationally, teams should avoid assuming the nature of changes within FRM-0360A/FRM-0360B or within the GUI-0102 guidance itself without reviewing the currently posted documents and comparing to any prior controlled versions in their quality systems.

For next steps, PV Quality Leads—supported by Medical Device Vigilance Leads and Regulatory Intelligence—can (1) download FRM-0360A and FRM-0360B from Health Canada and confirm internal template libraries and recall workflow tooling reference the correct form IDs and required fields, and (2) retrieve the May 22, 2026 GUI-0102 and log any needed process/document updates via CAPA after a targeted gap check for Canada inspection readiness.

This is a near-term readiness item for Canada operations ahead of the next recall submission or Health Canada interaction, with ongoing monitoring of Health Canada compliance/enforcement postings and GUI-0102 updates as part of routine regulatory intelligence review.

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

Urgency: High

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Technical Guidance
Read impact briefarrow_forward
publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Urgency: High

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward